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ABSTRACT  
Objective: The current research was an attempt to formulate and design an extend release dosage form of zidovudine hydrochloride using various 
grades of ethyl cellulose (ethocel) such as ethocel 4CPS, ethocel 7 CPS and aqualon T10 Pharm EC with two grades of hydroxy propyl methyl 
cellulose (HPMC K4M and HPMC K15M).  
Methods: Pilot scale batches of nine formulations were prepared using kollidon and adopting wet granulation technique. Physiochemical properties 
of tablet and granules were examined prior compression to get tablet. Tablets were characterized as drug content, percentage weight variation, 
thickness, Hardness, percentage friability and in vitro drug release pattern and studied for 12 hour in USP Type-II apparatus using 900 ml 
Phosphate buffer at 37±0.5 °C. The dissolution release profile of drug in tablet was performed by various drug release kinetic modelling.  
Results: The result revealed formulation F8 containing ethocel 7CPS and aqualon T10 was able to delay the pure drug release for 12 h and followed 
Higuchi pattern. Whereas; formulations containing only ethocel 4CPS provided earlier drug release. Dissolution data of promising formulation were 
analysed with innovator formulation for similarity factor (f2), exhibited an acceptable value more than 50. FT-IR (fourier-transform infrared 
spectroscopy) and DSC (differential scanning calorimetry) study revealed no such incompatibility found between the pure drug and polymers but 
slight change in crystalinity were observed in XRD study (X-ray diffraction). SEM (scanning electron microscope) study revealed very rare 
intragranular pore and cavity.  
Conclusion: From that, it can be marked as viscosity and selection of ethocel have great importance in delay drug release.  
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Oral drug delivery is that the most generally used routes for 
administration of medicine, which are explored for general delivery 
via numerous pharmaceutical products as completely different dose 
kind [1]. In long-run medical care for the treatment of chronic 
disorders, typical formulations are needed to be administered 
oftentimes in multiple dose regimens, and thus have many 
undesirable effects. therefore so as to cut back the disadvantage 
related to multiple dosing, controlled or sustained unleash solid unit 
dosage forms as tablets were developed [2]. They typically produces 
higher patient compliance, maintain uniform drug therapeutic level, 
price effectiveness, broad regulative acceptance, cut back dose 
similarly as aspect effects and increase margin of error for top 
efficiency therapeutic agents [3]. 
HIV (human immune deficiency virus), the virus that causes AIDS, 
“acquired immunodeficiency syndrome,” has become one in every of 
the world’s most serious health and development challenges. The 
primary cases were reported in 1981 and these days. There are unit 
roughly thirty seven million individuals presently living with HIV 
and tens of countless individuals have died of AIDS-related causes 
since the start of the epidemic. Whereas new cases are reported 
altogether regions of the globe, roughly two-thirds area unit in 
geographic region, with forty third of latest cases in eastern and 
Southern continent [4]. 
Zidovudine comes in category of drugs known as nucleoside reverse 
transcriptase inhibitors-NRTIs. This drug together with other 
concurrent HIV medicine to help control spreading of retroviral 
infection [5]. It helps to decrease the amount of spreading HIV 
infection in body so that our immune system does better. This 
lowers chance of getting HIV complications and improves patient 
quality of life. This drug has more contribution towards prevention 
of HIV infection from infected mother to newborn. However serious 
side effects also marked in certain cases such as lactic acidosis, 
myopathy, weakness, immune reconstitution inflammatory 
syndrome, blood anemia, unusual breathing, dark color urine, 
neutropenia, muscle pain etc [6]. Such above mentioned cases 
always associated in chronic administration of dosage. In order to 
reduce such kind of severe and ill effect to patients controlled and 
fabricated dosage form are always being proved one step forward in 
proving safety and efficacy. Very few literature studies have been 
reported in use of ethyl cellulose and hydroxyl propyl methyl 
cellulose (HPMC) in matrices drug delivery. Generally the controlled 
dosage forms or matrix tablets are fabricated by selecting suitable 
hydrophilic and hydrophobic polymer [7, 8]. Hence novelty of the 
proposed work is to use various grades of ethocel in combined use of 
HPMC in a matrix tablet of anti retroviral drug. 
Thus, an attempt has been made to formulate the extended-release 
matrix tablets of zidovudine HCl and affect of various grades of 
ethocel such as ethocel 4CPS, ethocel 7CPS and aqualon T10 Pharm 
EC on release of zidovudine were also observed and studied. During 
the study various findings were observed and those interpretated 
data could be used in large scale production.  
MATERIALS AND METHODS 
Materials 
Zidovudine HCl was received as gift sample from Cipla LTd, Mumbai. 
Hydroxy-propyl methyl cellulose (HPMC K4M, HPMC K15M) and 
ethyl cellulose (ethocel 4CPS, ethocel 7CPS and aqualon T10 Pharm 
EC) were purchased from Loba Chemie, Mumbai, India. Dicalcium 
phosphate and polyvinyl pyrolidone (kollidon 30) were purchased 
from BASF Global (Germany). Colloidal silicon dioxide (aerosil-R 
972) was received as gift sample from Ajanta ltd, India. All remain 
high analytical grades of chemicals, solvent and iso propyl alcohol 
(IPA) was purchased from Merck chemicals, India.  
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Method for preparation of tablets 
Zidovudine HCl, HPMC K4M, HPMC K15M, dicalcium phosphate, 
ethocel 4CPS, ethocel 7CPS aqualon T10 Pharm EC and kollidon CL-
SF were passed through #70 mesh and collected separately in 
polyethylene bag (table 1). Wet granulation technique was applied 
for the batch preparation of matrix tablets. All the materials were 
sifted to rapid mixing pilot scale granulator (SSPM System and 
Engineers, India) and mixed for 30 minute at optimized speed. 
Kollidon-30 was dissolved in the mixture of iso propyl alcohol (IPA) 
and Water (1:0.7) by the help of mechanical stirrer [9]. The above 
binder solution was added to dry mix and mixed for 20 minute to get 
wet mass. Then the resulted wet mass was dried at inlet 
temperature of 55 °C to 65 °C for 30 min and passed through multi 
mill (Bectochem, Ahmehdabad, India). The resulted dried granules 
were sifted through #16 mesh and milled through Multi mill. The 
comminuted granules were lubricated with aerosil-R 972 for 10 min. 
Finally, the lubricated granules were compressed to formulate 
tablets using tablet compression machine (Cadmach Machinery Pvt. 
Ltd, Puna, India) with 10 mm spherical shaped punches [10, 11]. 
 
Table 1: Composition of tablet formulation (mg) 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Zidovudine Hydrochloride 250 250 250 250 250 250 250 250 250 
2 Dicalcium phosphate 150 150 150 150 150 150 150 150 150 
3 Ethocel 4CPS 10 - - 5 5 - - 5 10 
4 Ethocel 7 CPS - 10 - - 5 5 - - - 
5 Aqualon T10 Pharm EC - - 10 5 - 5 10 5 - 
6 HPMC K4M 25 25 25 25 - - - - - 
7 HPMC K15M - - - - 25 25 25 25 25 
8 Kollidon 30 40 40 40 40 40 40 40 40 40 
9 Isopropyl Alcohol q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
10 Aerosil R 972 5 5 5 5 5 5 5 5 5 
 Total Weight(mg) 480 480 480 480 480 480 480 480 480 
 
Micromeritic properties of prepared granules 
Prior to compression, granules were evaluated for their 
characteristic parameters [12]. Angle of repose was determined by 
funnel method. Bulk density (BD) and tapped density (TD) were 
determined by cylinder method, and carr’s index (CI) was calculated 
using the following equation  
CI= (TD-BD)/TD ×100. . . . . (1) 
Hausner’s ratio (HR) was calculated by the following equation 
HR=TD/BD. . . . . . . . (2) 
Physical characterization of matrix tablets 
The physiochemical characterizations of tablets were analyzed 
such as Hardness, friability, weight variation thickness and assay 
of compressed matrix tablet for each formulation were 
determined. Tablet hardness test was determined for 20 tablets 
using tablet hardness tester (Pfizer Tester) and the data reported 
is the mean of triplicate. Friability test was assessed to measure 
the strength of tablets as result to withstand mechanical shock, 
wears and tears. Preweighed randomly selected ten tablets were 
placed in a Roche friability tester and operated for 100 rpm. As per 
the limit of standardization the difference in weight should not 
more than 1% of their weigh. A weight variation test was 
performed according to USP30 NF25 on 20 tablets by taking 
samples from a batch after production of every 50 tablets and 
randomly from a total batch of 100 tablets using an electronic 
balance (Scientech SE-391, India). The thicknesses of tablets were 
measured by digital vernier callipers (Mitatoyo, Japan). The drug 
content in terms of assay of each batch was determined in 
triplicate. For each batch a number of 20 tablets were weighed and 
crushed to fine powder using mortar and pestle. An accurately 
equivalent weighed of 480 mg of the powder was taken, crushed 
and suitably dissolved in methanol and analyzed by HPLC (high 
performance liquid chromatography) after making appropriate 
dilutions. The procedure was carried out on Shimadzu LC-2030 LT 
with flow rate of 0.5 ml/minute at ambient temperature. 
In vitro dissolution studies 
In vitro release study was performed using United States pharmacopoeia 
(USP) dissolution testing apparatus II (paddle method). The dissolution 
test was performed using 900 ml of Phosphate Buffer of pH 6.8 at 37±0.5 
°C and 50 rpm was fixed. At period of one hour interval 10 ml sample 
solution were withdrawn and passed through membrane filter of 0.45 
μm. Samples were collected for time period of 12 h. They were diluted 
with fresh phosphate buffer at suitable concentration and absorbances 
of those solutions were measured at 266 nm using a Shimadzu UV-2600 
UV/Vis double beam spectrophotometer. The data represented in table 
in triplicate. 
Comparison of dissolution profile 
The similarity factor (f2) given by scale up and post approval 
changes (SUPAC) guidelines [13] for a modified release dosage form 
was used as a basis to compare dissolution profile. The dissolution 
profiles are considered to be similar when f2 is between 50-100 and 
dissimilarity factor (f1) lies below 15. The dissolution profiles of 
product was compared to Innovator (Zidine, Emcure-Innovator) 
using f2 and f1which are calculated from the following formule, 
f2=50×log {[1+(1/n) ∑ t=1 n | R t–T t|2]- °.5× 100}. . . (3) 
f1= {[∑ t=1n | R t–T t|]/[∑ t=1n R t]} × 100. . . . . (4) 
Where, n is the number of dissolution sample times and Rt and Tt are 
the individual or mean percent dissolved at each time point, t, for the 
innovator and test dissolution profiles, respectively. 
RESULTS AND DISCUSSION 
Micromeritic properties of granules 
Micromeritic properties of precompressed granules were evaluated 
and cited in table 2. The angle of repose found to be within limit of 
33±3.83 to 41±1.75. Tapped density was between 0.502 to 0.593 
and bulk density was found between 0.415 to 0.467. The result cited 
in table indicated good flow as it varied from 33 to 41. In addition to 
that, carr’s index found to vary from 11.04 to 28.66, which indicates 
good compressibility [14]. 
Physical characterization of matrix tablets  
Physiochemical characterization of tablets were studied and displayed 
in table 3. The hardness of tables ranged from 4.9 kg/cm2 to 5.9 
kg/cm2. During the study it observed that, formulations having ethocel 
grades of low viscosity have high crushing strength as compared to 
higher viscosity grades of ethocel as observed in aqualon T10 pharm 
EC. Formulation F1 exhibited higher crushing strength of 5.9 kg/cm2as 
it contained ethocel 4CPS and HPMC K4M. This is explained by the fact 
that ethocel of lower viscosity grades are more compressible and 
produced more harder tablet as observed during the study [15]. As per 
US pharmacopoeia the maximum percentage friability should not 
exceed 1%. The prepared tablets lies within the acceptable and passed 
the friability test ranged from 0.17 to 0.45. All the tablets showed 
excellent uniform thickness and no such variation was found. Average 
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weight of each tablet ranged between 480.1±0.53 mg to 482.1±1.07 
mg. As per pharmacopoeia standard the weight of tablet more than 
324 mg should not beyond 5% w/w [16-18]. The prepared tablet 
weight variation within the specified limit acceptance. Percentage of 
drug content in tablet found to be within the acceptable limit of 
97.68% to 102.35%. 
 
Table 2: Micromeritic properties of prepared granules 
 S. No. Formulation 
code 






Compressibility index (Carr’s 
index) 
Angle of repose 
(X±SD) 
1 F1 0.423±1.17 0.502±1.36 1.18 15.73 40±1.58 
2 F2 0.428±2.11 0.581±2.63 1.35 26.33 41±1.75 
3 F3 0.467±2.1 0.525±2.84 1.12 11.04 37±2.84 
4 F4 0.423±1.51 0.581±1.49 1.37 27.19 35±2.83 
5 F5 0.415±2.19 0.583±2.01 1.4 28.81 35±1.06 
6 F6 0.425±1.61 0.572±1.39 1.34 25.69 33±3.83 
7 F7 0.431±3.01 0.591±1.83 1.37 27.07 38±2.94 
8 F8 0.423±2.11 0.593±1.52 1.4 28.66 37±2.05 
9 F9 0.425±1.42 0.514±2.85 1.2 17.31 39±2.52 
Data are represented as mean±standard deviation (SD), n=3 
 
Table 3: Physical characterization of the designed formulations 
 S. No. Formulation 
code 










1 F1 480.1±0.53 4.27±1.01 5.9±2.45 98.38±2.19 0.18% 
2 F2 481.3±2.29 4.17±1.12 5.2±1.46 102.35±3.17 0.32% 
3 F3 482.0±1.27 4.18±2.23 5.6±2.55 99.18±2.47 0.26% 
4 F4 481.6±0.29 4.3±1.27 5.4±3.06 98.27±3.16 0.28% 
5 F5 482.1±0.28 4.26±0.98 5.2±2.72 99.25±1.39 0.45% 
6 F6 480.5±1.15 4.26±0.35 5.0±3.25 97.68±1.48 0.17% 
7 F7 482.1±1.07 4.27±0.87 4.9±3.14 100.01±4.52 0.31% 
8 F8 480.6±0.57 4.26±1.17 5.1±2.45 100.67±1.09 0.27% 
9 F9 480.2±1.12 4.26±1.12 5.4±2.78 99.09±3.08 0.19% 
Data are represented as mean±standard deviation (SD), n=3 
 
In vitro dissolution studies 
Different grades of ethocel like ethocel 4CPS, 7CPS and aqualon T10 
were used to formulate zidovudine hydrochloride matrix tablet. The 
dissolution studies were performed in Phosphate Buffer of pH 6.8 for 
maximum time period of 12 h as displayed in fig. 1. In all the 
formulations the percentage of ethocel were fixed at 2 % but the 
varied in grades of ethocel. The binder solution kollidon was fixed at 
8% in all formulation. During the study the effect of two grades of 
HPMC such as HPMC K4M and HPMC K15M with ethocel were also 
studied. Result showed time needed for 100% of drug release from F8 
was 12 h, while F1 released 100% drug release within only 3 h. It also 
observed that formulation F6 prepared with ethocel 7 CPS and 
aqualon T10 pharma EC release only 84.5 % at 12 h. This clearly 
indicated that, as ethocel 7 CPS replaces 4CPS; the drug release also 
extended for another 2 h. From that point of view it could be 
concluded that as the more viscous grades of ethocel use; 
progressively the drug release also extended as observed in F7 and F9. 
Formulation F9 containing ethocel 4CPS at 2% released to 100 %, 
where as F7 contained T10 pharma EC released only 72% on 12 h. 
During the study, it also observed formulations containing HPMC 
K15M delayed drug release as compared to formulations prepared by 
HPMC K4M except F9, as the formulation contained only ethocel 4CPS. 
From the experiment it can also be remarked that, as the polymer 
viscosity increases the extent of release also increases and vice versa. 
In this study an remarkable finding was observed that, though the 
formulations containing lower viscosity grades of polymer and have 
higher crushing strength but the polymers having higher viscosity 
such as HPMC K15M prolonged the drug release to certain extend [19]. 
The data obtained from in vitro dissolution studies were fitted to 
zero-order, first-order, and higuchi release kinetics. All formulations 
were best fitted either to zero order or higuchi. The best fit with 
higher correlation coefficient (r2>0.997) was found with higuchi’s 
equation for F8 and concluded the release of drug from tablet 
involves both dissolution and diffusion through polymers. To 
assertain the exact mechanism of drug release, the data were fitted 
by korsemeyer-peppas equation. The “n” value lies between 0.41 to 
0.51. Hence it can be inferred that the release was based on quasi 
fickian and the release of drug had great impact by those 
hydrophobic polymer. On the basis of the above results, F8 was 
selected and preceded for further study. 
 
 
Fig. 1: In vitro dissolution study of all formulations, (Data are represented as mean±standard deviation (SD), n=3) 
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Comparison of dissolution profile 
The comparative results of the selected formulation batch F8 was 
compared with the theoretical dissolution profile (Zidine, Emcure-
Innovator) using the similarity factor f2 test and dissimilarity factor 
f1 test. The results of the similarity tests showed that formulation F8 
had f2 value>50 i.e. 64, indicating the closest fit to the dissolution 
profile of innovator. 
Drug polymer interaction study 
FT-IR study 
Pure zidovudine HCl mixed with ethocel 4CPS, ethocel 7CPS, aqualon 
T10 pharm EC dicalcium phosphate separately with IR grade KBr 
and pellets were prepared by applying a pressure of 10 tons in a 
hydraulic press. The pellets were scanned over a wavelength range 
of 450 to 4,500 cm-1 using an FTIR IRSpirit, Schimazu. There was no 
chemical interaction between zidovudine hydrochloride and the 
polymers used which is obtained by employing I. R. spectral studies 
(fig. 2 and fig. 3). The characteristic peak of carbonyl group at 
1685.84 cm-1 and azide group at 2083.19 cm-1 indicated the stability 
of drug before and after formulation. 
DSC study 
Differential scanning calorimetry (DSC) has shown to be an 
important tool to quickly obtain information about possible 
interactions between the active and the excipients, according to the 
appearance, shift or disappearance of endothermic or exothermic 
peaks. DSC study was performed using Perkin Elmer DSC to 
determine the drug excepient compatibility study. During study a 
sharp endothermic peak for zidovudine hydrochloride was obtained 
at 131.55 °C corresponding to melting point (fig. 4). But in the 
formulation there was a slight change in peak temperature such as 
106 °C and 180 °C (fig. 5), also a slight change in peak area and peak 
shape changed, which might be due to reduction of the purity 
percentage of component, appearance of adjacent polymer and 
interaction with solvent excipients [20, 21]. 
 
 
Fig. 2: FTIR spectrum of pure zidovudine hydrochloride 
 
 
Fig. 3: FTIR Spectrum of formulation F8 
 
 
Fig. 4: DSC curve of pure zidovudine hydrochloride 
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Fig. 5: DSC curve of formulation F8 
 
XRD study 
Change in crystalinity of drug can be determined by this technique. 
Pure drug and formulation components were analysed by the help of 
XRD 7000, Shimadzu [22]. Pure zidovudine HCl showed the classical 
diffractogram of the crystalline substance. The XRD pattern of the 
formulation showed slight change in peak and pattern, indicated 
slight loss of crystalinity (fig. 6 and fig. 7). 
  
 
Fig. 6: XRD of pure zidovudine hydrochloride 
 
 
Fig. 7: XRD of formulation F8 
 
 
Fig. 8: SEM study of formulation F8 granules 
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SEM study 
In order to observed the surface morphology of prepared granule 
SEM Study was performed. It observed surface of granules were 
smooth and very rare intraparticular space (fig. 8). The studies 
revealed the surface of granules were covered well by ethocel; might 
be able to retard the free release of drug from tablet because of 
hydrophobic character [23] as compared to dummy granules 
prepared only by HPMC (not included in table 1). 
Stability study of best batch  
Long term, intermediate and accelerated stability testing study was 
carried out according to ICH guidelines considering 25±2 °C/60±5% 
RH, 30±2 °C/65±5% RH and 40±2 °C/75±5% RH respectively. One 
hundred tablets of batch F8 were securely packed in aluminium 
blister and placed in humidity chamber [24]. There was no such 
major significance change in hardness and drug assay at a regular 
interval of 3 mo during the study of 24 mo as shown in table 4. 
 
Table 4: Stability study of best batch 
Long term stability study (25±2 °C and 60±5% RH) 
Month 3 6 9 12 18 24  
Drug assay (%) 100.34±1.26 100.15±2.17 99.13±1.36 99.09±2.65 99.22±2.97 98.17±1.49 
Crushing strength  
(Kg/cm2) 
5.8±4.15 5.8±2.15 5.8±1.58 5.7±2.28 5.7±2.71 5.8±3.45 
   Intermediate stability (30±2 °C and 65±5% RH) 
Month 3 6 9 12 18 24 
Drug assay (%) 100.14±2.26 100.35±1.31 99.47±0.96 99.49±1.73 99.67±3.15 98.31±1.23 
Crushing strength  
(Kg/cm2) 
5.8±2.51 5.8±2.06 5.8±1.27 5.8±1.08 5.8±1.8 5.7±2.05 
   Accelerated stability (40±2 °C and 75±5% RH) 
Month 1 2 3 6 - - 
Drug assay (%) 100.07±3.15 100.34±2.11 99.98±1.02 99.25±2.51 - - 
Crushing strength  
(Kg/cm2) 
5.8±1.69 5.8±1.4 5.8±1.09 5.7±2.15 - - 
Data are represented as mean±standard deviation (SD), n=3 
 
CONCLUSION 
During this study extended release tablet of zidovudine HCl tablets 
were formulated. A total number of nine formulations were 
prepared by varying the amount of ethocel and HPMC. In this study 
the effect of various grades of ethocel with combination of HPMC 
studied. Result showed time took for F8 to release 100% drug was 
12 hour. Moreover, it also observed that as viscosity of ethocel 
increased progressively extended the drug release. Formulation F8 
compared with innovator and found to be providing satisfactory 
result. Furthermore, industrial grades of reproducible bathes and in 
vivo pharmacokinetic study have to carry out. 
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